江苏恒瑞医药股份有限公司关于2022年员工持股计划部分份额解锁条件成就暨第三个锁定期届满的提示性公告

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has announced the completion of the third lock-up period for its 2022 employee stock ownership plan, with specific conditions for unlocking portions of the shares based on performance metrics [1][4][5]. Summary by Sections Employee Stock Ownership Plan Progress - The 2022 employee stock ownership plan was approved during meetings held on August 19, 2022, and September 8, 2022 [1][2]. - A total of 12 million shares were transferred to the employee stock ownership plan account at a price of 4.97 yuan per share [2]. - The first meeting of the plan's participants was held on November 7, 2022, where a management committee was established to oversee the plan [3]. Lock-up Period and Unlocking Conditions - The employee stock ownership plan has three unlocking phases: 40% after 12 months, 30% after 24 months, and 30% after 36 months [4][5]. - The third lock-up period ended on November 7, 2025, and the management committee will manage the rights of the participants based on market conditions [5]. Performance Assessment for Unlocking - Company-level performance metrics include sales revenue from innovative drugs, the number of new molecular entity IND approvals, and the number of NDA applications accepted [6][7]. - For the third unlocking phase, the company achieved over 32 billion yuan in cumulative innovative drug revenue, more than 33 IND approvals, and over 21 NDA applications, meeting the 100% unlocking criteria [6]. Subsequent Arrangements Post Unlocking - After the third lock-up period, the management committee will handle the rights of the participants according to the employee stock ownership plan [7][8]. New Employee Stock Ownership Plan - The company has initiated a new employee stock ownership plan for 2025, with 13.51 million shares transferred at a price of 30.95 yuan per share, representing 0.20% of the total share capital [10][11]. - The new plan will also have three unlocking phases similar to the previous plan, with performance assessments determining the actual unlocking ratios [11]. Clinical Trial Approvals - The company has received approval for clinical trials of SHR-4610 injection, an innovative anti-tumor drug, and HRS-2430 injection, a general anesthetic, indicating ongoing investment in R&D [19][24]. - The total R&D investment for SHR-4610 is approximately 7.36 million yuan, while HRS-2430 has seen an investment of about 24.6 million yuan [21][25].